ARDX Historical PE Ratio Notes

— Ardelyx (“ARDX”) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to improve treatment for cardiorenal and gastrointestinal diseases. Its pipeline is anchored by its FDA-approved drug Xphozah, used as an adjunctive therapy for adults with chronic kidney disease (“CKD”) on dialysis who suffer from high serum phosphorus levels. Historically, ARDX's price-earnings (PE) ratio has been volatile or even negative, largely due to the company's unprofitability in most years—a common trait for biotech firms investing heavily in R&D before attaining commercial revenue. As you review historical price, earnings, & PE ratio data, you'll notice that periods without positive net income will result in no meaningful or negative PE ratio values, reflecting both the risk and opportunity the market associates with Ardelyx. The potential for successful drug launches & revenue growth decisively shapes ARDX's valuation, as investors often look past near-term losses in anticipation of future profitability. Therefore, understanding the company's clinical milestones, regulatory approvals, and commercialization trajectory is key when interpreting historical valuation metrics such as the PE ratio.

On this page we presented the Ardelyx Historical PE Ratio information for Ardelyx' stock. The average ARDX historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 25.1. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ARDX historical PE based on this TTM earnings result method is NA. Note: any PE calculations resulting in a value exceeding 500 were discarded as not meaningful. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ARDX historical PE result, against the recent PE: when this page was posted on 5/6/2026, the most recent closing price for ARDX had been 7.10, and the most recent quarterly earnings result, annualized, was 0.08. Meanwhile, the most recent TTM earnings summed to 0.02. From these numbers, we calculate the recent ARDX PE on 5/6/2026 based on annualized quarterly EPS was 88.8. Based on ARDX's history, that recent PE is elevated relative to the historical average, with the recent PE 253.8% higher than the historical average PE across our data set for Ardelyx.

For self directed investors doing their due diligence on ARDX or any other given stock, valuation analysis for ARDX can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Ardelyx PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ARDX. Thanks for visiting, and the next time you need to research ARDX Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.